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A B S T R A C T
Study objective: The aim of this study was to compare methadone and morphine for the management of post-
operative.
Design: Open, controlled study.
Setting: Postoperative recovering area, ward.
Patients: Sixty-four patients, ASA I-III, undergoing gynecological surgery for cancer.
Interventions: Morphine or methadone 0.15mg/kg given preoperatively. After operation an intravenous mor-
phine or intravenous methadone infusion at doses of 12mg/day was started.
Measurements: Pain intensity and opioid consumption.
Main results: Methadone infusion provided a better analgesia in comparison with morphine infusion on the
second day. Opioid consumption was significantly lower in the methadone group. No episodes of relevant de-
saturation or signs of respiratory depression were recorded.
Conclusion: A preoperative bolus of methadone, followed by a continuous infusion of low doses post-operatively,
provided a better analgesia, without adding risk of adverse effects, in comparison with morphine.
1. Introduction
Adequate postoperative pain control is an important part of perio-
perative medicine. Inappropriate perioperative pain management has
numerous physiologic complications and is responsible of unnecessary
suffering [1]. Regretfully, many patients remain undertreated. It has
been reported that> 40% of patients report inadequate pain relief or
pain of moderate intensity or greater in the postoperative period, de-
spite treatment [2,3]. Of concern, unrelieved postoperative pain in-
creases risk of developing chronic post surgical pain [1].
Intravenous patient-controlled analgesia (PCA) has become the
mainstay for providing postoperative pain relief over the past years
[4–6]. However, PCA may have some limitations. While PCA may re-
duce nursing time, the cost of pumps, disposables, and adverse events
should be considered in balancing the overall cost-effectiveness of PCA.
[7]. For many years a long-available effective drug, such as methadone,
has been underutilized. Despite methadone being a cost-effective an-
algesic for acute, chronic, neuropathic, and cancer pain, and can be
administered via oral and parenteral routes [8], its use in the operating
room and postoperatively is a neglected issue [7]. Only few old studies
have assessed methadone for postoperative pain [9–12]. These studies
were performed in a mixed population undergoing different surgeries
and were principally based on a pre-operative administration of a me-
thadone bolus.
The primary aim of this study trial was to compare the effects of
methadone on pain scores with those of morphine for postoperative
pain in patients undergoing a standard operation, like hyster-
osalpingectomy for gynecological cancer. In addition, the analgesic
requirements and possible adverse effects induced by opioids were
determined.
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2. Methods
This was a randomized, active-controlled, study. The study protocol
and statement of informed consent were approved by the institutional
review board Ethical approval for this study (Ethical Committee N° 6/
2013) was provided by the Ethical Committee of the University of
Palermo. All patients provided written informed consent. Patients were
recruited in a period of two years.
Patients scheduled for open hystero-salpingectomy for gynecolo-
gical cancer under general anesthesia were enrolled. Non-pregnant fe-
male patients were eligible for inclusion if they were at least 18 years
old and had an American Society of Anesthesiologists physical status I
to III. Patients were excluded if they were receiving opioids for chronic
pain or for any other reason, had documented sleep apnea, alcohol or
drug abuse, oxygen saturation of< 92%, had any medical condition
that would interfere with pain assessment. The use of any drug that
would affect postoperative pain levels, such as gabapentinoids, steroids,
or anti-inflammatory drugs was not allowed intraoperatively or post-
operatively. Patients with a chronic pain condition necessitating treat-
ment with these agents were also excluded from the study. Patients had
to be withdrawn from the study if the oxygen saturation could not be
maintained at ≥92% with supplemental oxygen (3 L/min), if the re-
spiratory rate could not be maintained at 8 breaths/min or greater, or if
excessive sedation occurred.
2.1. Procedures
Patients scheduled for the first operation during the day (performed
at 8 AM), were randomized by a computerized system to receive mor-
phine (group 1) or methadone (group 2). A total of 64 participants were
randomized chronologically in a 1:1 ratio according to the random
coding table and were given the corresponding medication.
Patients were premedicated with midazolam 0.1mg/kg, plus mor-
phine or methadone 0.15mg/kg, intravenously. During surgery, in-
travenous fentanyl was allowed as needed for analgesia. Nasogastric
tube was not inserted. Following surgery, boluses of the study drugs in
doses of 3mg were given to keep the patient comfortable in the post-
anesthesia care unit (PACU) if their pain intensity was ≥4/10. These
doses were computed in opioid consumption calculation on the op-
eration day. Pain intensity was based on an 11-point numerical rating
scale (NRS), where 0=no pain and 10=worst possible pain.
Metoclopramide 5mg and clonidine 75 μg were given in case of vo-
miting and shivering, respectively, during PACU stay.
At discharge from the PACU, an intravenous morphine or metha-
done infusion was given, at doses of 12mg/day. Paracetamol was given
first at request of patients. Extra-doses of morphine or methadone in
doses of 3mg were given as breakthrough medication. Patients were
educated about asking for opioid analgesia when pain was considered
no longer acceptable. The use of metoclopramide was permitted for
controlling nausea and vomiting.
Comorbidities and some parameters such as, pain intensity (nu-
merical scale 0–10), the level of nausea, drowsiness, and itching (from 0
to 3), episodes of desaturation (< 92%) were recorded since the patient
was transferred to the surgical ward at 12 AM, and 2, 4, 6, 8, and 10 PM
on the operation day, labelled as T1, T2, T3, T4, T5, and T6, respec-
tively. On the second day, these parameters were measured at 6 and
10 AM, and 2, 6, and 10 PM, labelled as T7, T8, T9, T10, and T11,
respectively. Opioid consumption was recorded in the PACU and in the
surgical ward on the operation day, and on the second day.
The primary efficacy end point was the pain intensity at the dif-
ferent time intervals on operation day and on the second day.
Secondary end points included the pain intensity differences (PID), and
the time-weighted summed pain intensity difference over 48 h
(SPID48), as well as the opioid consumption, as extra-doses of the study
drugs given at patients' request.
2.2. Statistical analysis
To achieve the primary end point, a sample size of 20 patients per
treatment group yields a statistical power of 80% with a Type 1 error of
0.05, allowing the detection of a difference of 0.5 in mean pain in-
tensity score (with a standard deviation of 0.5). The within-group
standard deviation is assumed to be 3, with a percentage of missing
data of 20%. The sample size was inflated by 40% to account for
missing data, attrition, and protocol violations.
Statistical analysis of quantitative and qualitative data, including
descriptive statistics, was performed for all items. Continuous data are
expressed as mean ± SD, unless otherwise specified. Frequency ana-
lysis was performed using the Pearson's chi-square test and Fisher exact
test, as needed. The univariate analysis of variance (ANOVA) was
performed to evaluate mean differences (age, weight, and opioid con-
sumption) between patient groups. Whereas some variables were not
normally distributed, we have used non-parametric tests and in parti-
cular the related-samples Friedman's two-way analysis of variance by
ranks test (for intragroup comparison) and the independent-samples
Mann-Whitney U Test for intergroup comparison. Data were analyzed
by IBM SPSS Software 22 version (IBM Corp., Armonk, NY, USA). All P-
values were two-sided and P < 0.05 was considered statistically sig-
nificant.
3. Results
Sixty-four patients met the inclusion criteria. Four patients had in-
complete data. Thus, 60 patients were examined (32 and 28 patients in
group 1 and 2, respectively). The flow diagram, according to CONSORT
guidelines is reported in Fig. 1. The mean age was 56.3 years (SD 9.6),
and the mean weight was 64.6 kg (SD 9.4). No differences between the
two groups were found (P=0.799 and 0.909, respectively). Fifty, nine,
and one patients were ASA II, III and I, respectively, with no differences
between the groups (Fisher's exact test P= 0.209). Also the distribution
of comorbidities in morphine vs methadone group was similar for hy-
pertension (12 vs 14 patients respectively, Fisher's exact test
P= 0.435), diabetes (2 vs 5 patients respectively, Fisher's exact test
P= 0.235), chronic respiratory disease (2 vs 1 patients respectively,
Fisher's exact test P=1.0), and obesity (6 vs 3 patients respectively,
Fisher's exact test P= 0.482). No episodes of relevant desaturation
were recorded and no patient presented signs of respiratory depression.
The changes of parameters recorded at the different time intervals
on the operation day and on the second day are shown in Tables 1 and
2. Pain intensity progressively changed in both groups. Methadone in-
fusion provided a better analgesia in comparison with morphine infu-
sion on the second day. PID at the various intervals and SPID48 are
reported in Tables 3 and 4, respectively. The difference was significant
for PID at the last measurements on the second day. Lower values of
SPID48 were found in the methadone group, although the difference
was not significant different between the two groups.
Intravenous paracetamol was used in 20 and 14 patients in mor-
phine and methadone groups, respectively (Fisher's exact test
P= 0.435). Opioid consumption was significantly lower in the me-
thadone group (Table 5).
4. Discussion
The findings of this study suggest that a preoperative dose of me-
thadone, followed by a continuous infusion of low doses of methadone,
provided better postoperative analgesia in patients undergoing in
comparison with morphine in patients undergoing gynecological pro-
cedures. Moreover, analgesic consumption including paracetamol and
study drugs was significantly lower in patients receiving methadone.
This analgesic effect was not associated with more adverse effects
among those commonly induced by opioids.
These findings are explained by several pharmacologic and clinical
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studies, although few trials assessed the value of methadone as a
postoperative analgesic drug. It still remains a misunderstood drug [7],
possibly due to some misconception about its use in the perioperative
setting, due to its onset, duration, and metabolism. The onset of me-
thadone is relatively fast, comparable to fentanyl, as central nervous
system effect site methadone concentrations rapidly equilibrate with
plasma concentrations [13], corresponding to the time course of miosis.
Of interest, a lag time exists for the central nervous system compart-
ment penetration and the onset time of morphine [14]. Thus metha-
done can be considered as a rapid-onset drug, with an onset time si-
milar to that of fentanyl.
It has been reported that the duration of methadone analgesia is
shorter than its elimination half-life. However, this observation is also
true for other opioids as well other drugs [15,16]. Targeting doses and
concentrations above the minimal analgesic concentration but below
the threshold for respiratory depression, should provide a lasting an-
algesia and minimal central adverse effects. Of interest, a calibrated
continuous infusion with low doses may overcome the problem, as it
occurred in this study. Although methadone has a highly variable
clearance and a large potential for drug interactions [17], these inter-
ferences are often subclinical [7,18].
Pioneer investigations on methadone in the perioperative period
were reported about 30 years ago [9–12]. An intravenous bolus of
20mg of methadone, after induction of anesthesia, determined a
complete analgesia in approximately one-third of patients, and no an-
algesic requests during the 72 hour postoperative observation period
were reported. Only one third of patients requested some postoperative
opioid drugs, and the mean time to first opioid analgesic request was
20 h. These outcomes were achieved without reporting relevant adverse
effects.
After many years, data regarding the use of methadone in the
perioperative setting still remain poor, particularly in abdominal cancer
surgery. In patients undergoing hip arthroplasty a continuous infusion
of 24mg/day of methadone with PCA boluses of 1mg, determined a
lower opioid consumption and less pain in comparison with morphine,
while adverse effects were similar [19]. In a randomized trial, patients
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Fig. 1. CONSORT flow diagram.
Table 1
Changes of parameters recorded on the operative day (T1, T2, T3, T4, T5, T6 correspond to 12 AM, and 2, 4, 6, 8, and 10 PM, respectively.)
T1 T2 T3 T4 T5 T6 P intergroupa
Pain intensity Morphine 4.5 (2.1) 3.5§ (2.4) 2.3⁎ (1.9) 1.6⁎ (2.1) 0.9⁎ (1.4) 0.6⁎ (1.2) T1 P=0.018
T2 P=0.013
T3 P=0.009
Methadone 3.0 (2.2) 2.1^ (2.3) 1.2⁎ (1.4) 0.8⁎ (1.3) 0.5⁎ (1.2) 0.3⁎ (0.9)
Nausea Morphine 0.4 (0.9) 0.3 (0.7) 0.2 (0.5) 0.1 (0.3) 0.2 (0.7) 0.2 (0.4) T1 P=0.021
Methadone 0.04 (0.2) 0.1 (0.3) 0.1 (0.3) 0.3 (0.7) 0.1 (0.4) 0.2 (0.7)
Vomiting Morphine 0.03 (0.2) 0.06 (0.2) 0.09 (0.3) 0.0 (0.0) 0.06 (0.2) 0.06 (0.2) NS
Methadone 0.04 (0.2) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.04 (0.2) 0.07 (0.2) NS
Drowsiness Morphine 1.5 (0.6) 1.5 (0.8) 1.2 (0.8) 1.1^ (0.6) 1.0§ (0.7) 0.5⁎ (0.5) NS
Methadone 1.3 (0.6) 1.3 (0.9) 0.9^ (0.7) 0.8^ (0.7) 0.7§ (0.8) 0.4⁎ (0.6) NS
Itching Morphine 0.03 (0.2) 0.03 (0.2) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) NS
Methadone 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) NS
^ P < 0.05 vs T0.
⁎ P < 0.0005 vs T0.
§ P < 0.005 vs T1, related-samples Friedman's two-way analysis of variance by ranks.
a Independent-samples Mann-Whitney U test.
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undergoing vertebral surgery, received an initial loading dose of
0.75 μg/kg sufentanil before surgical incision and a sufentanil infusion
of 0.25 μg/kg/h or methadone infusion, 0.2mg/kg, after intubation. In
comparison with sufentanil, methadone significantly reduced the
opioid consumption and pain scores in the postoperative period [20]. In
a similar surgical population, preoperative methadone 0.2 mg/kg con-
ferred a longer analgesia and less opioid consumption in comparison
with hydromorphone 2mg, given at the end of surgery [21,22], al-
though the doses chosen (about 15mg and 2mg, for methadone and
hydromorphone, respectively) should not be considered to be equiva-
lents [23]. According to these data, an initial priming with methadone
provided a prolonged and effective analgesia. These effects were at-
tributed to the slow rate of methadone elimination, and a N-methyl-D-
aspartate receptor antagonism [7].
In a gynecological cancer population similar to that examined in
this study, methadone and morphine in doses of 20mg were given after
induction of anesthesia. Patients who were administered methadone
required less methadone than morphine in the recovery room and on
the wards, and reported lower pain intensity scores [24]. Similarly, in
women undergoing abdominal hysterectomy, methadone or morphine,
0.25mg/kg were given preoperatively with further increments in the
recovery room for analgesia. Patients in the methadone group had
lower pain scores in the subsequent 48 h and had a less opioid con-
sumption [25]. Taken together, these data are consistent with a sus-
tained therapeutic analgesic effect in the postoperative period. In the
present study, a preoperative bolus of methadone and a postoperative
infusion of low doses provided superior analgesia over morphine, sug-
gesting that methadone is an effective and safe drug for postoperative
pain. Of interest, intravenous infusion of methadone has been used for
cancer pain management in opioid-tolerant patients, successfully [8].
There are some limitations of this study. Only women and a typical
gynecologic surgery were chosen. Gynecological procedures were
chosen as they are standard operations in terms of duration and po-
tential capacity to produce postoperative pain.
In conclusion, a preoperative bolus of methadone, followed post-
operatively by a continuous infusion of low doses provided a potent
Table 2
Changes of parameters recorded on the first postoperative day (T7, T8, T9, T10, and T11 correspond to 6 and 10 AM, and 2, 6, and 10 PM, respectively).
T7 T8 T9 T10 T11 P intergroupa
Pain intensity Morphine 2.3 (1.8) 2.0 (1.6) 1.0§ (1.1) 1.1§ (1.4) 0.5⁎ (0.8) T7 P < 0.0005
T8 P < 0.0005
T9 P=0.003
T10 P < 0.0005
T11 P=0.003
Methadone 0.6 (1.0) 0.6 (1.6) 0.3 (0.7) 0.07 (0.4) 0.0 (0.0)
Nausea Morphine 0.4 (0.7) 0.2 (0.4) 0.03 (0.2) 0.09 (0.4) 0.03 (0.2) NS
Methadone 0.5 (0.9) 0.3 (0.5) 0.1 (0.6) 0.07 (0.3) 0.1 (0.4)
Vomiting Morphine 0.2 (0.4) 0.0 (0.0) 0.03 (0.2) 0.03 (0.2) 0.0 (0.0) NS
Methadone 0.1 (0.4) 0.1 (0.3) 0.07 (0.3) 0.04 (0.2) 0.04 (0.2) NS
Drowsiness Morphine 0.7 (0.5) 0.7 (0.7) 0.4^ (0.6) 0.2# (0.5) 0.1# (0.4) NS
Methadone 0.6 (0.6) 0.4 (0.5) 0.2^ (0.4) 0.2^ (0.4) 0.1^ (0.3) NS
Itching Morphine 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) NS
Methadone 0.0 (0.0) 0.04 (0.2) 0.04 (0.2) 0.0 (0.0) 0.0 (0.0) NS
# P < 0.001 vs T0.
⁎ P < 0.0005 vs T0.
§ P < 0.005 vs T0.
^ P < 0.05 vs T0; related-samples Friedman's two-way analysis of variance by ranks.
a Independent-samples Mann-Whitney U test.
Table 3
Pain intensity difference at the selected intervals.
Operation day Second day
T1–T2 T2–T3 T3–T4 T4–T5 T5–T6 T1–T6 T7–T8 T8–T9 T9–T10 T10–T11 T7–T11
Morphine Mean (SD) 1.0 (2.4) 1.2 (2.1) 0.7 (1.7) 0.72 (1.6) 0.3 (1.1) 3.84 (2.1) 0.3 (2.0) 0.9 (1.4) 0.0 (1.6) 0.6 (1.0) 1.8 (1.7)
Methadone Mean (SD) 0.9 (2.5) 0.9 (1.9) 0.4 (0.9) 0.3 (1.2) 0.2 (0.5) 2.7 (2.4) 0.1 (1.8) 0.3 (1.5) 0.3 (0.8) 0.1 (0.4) 0.6 (1.0)
P intergroupa 0.826 0.487 0.152 0.210 0.758 0.057 0.767 0.007 0.835 0.006 0.005
a Independent-samples Mann-Whitney U test.
Table 4
SPID 48 in morphine and methadone groups.
N Mean Std. deviation Std. error 95% confidence interval for mean Minimum Maximum
Lower bound Upper bound
Morphine 32 29.2188 20.82451 3.68129 21.7107 36.7268 −20.00 62.00
Methadone 28 23.5714 21.58262 4.07873 15.2026 31.9403 −23.00 64.00
Total 60 26.5833 21.19185 2.73586 21.1089 32.0578 −23.00 64.00
P=0.378, independent-samples Mann-Whitney U test.
Table 5
Opioid consumption in the two groups; univariate analysis of variance (ANOVA
test).
N Mean DS P
Operation day Morphine mg 32 6,09 4,067 0.002
Methadone mg 28 3,11 2,998
Second day Morphine mg 32 2,25 2,851 <0.0005
Methadone mg 28 0,11 0,567
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analgesia, without adding risk of adverse effects, in comparison with
morphine. More information is needed about the effectiveness and
safety in outpatients, those who are opioid tolerant, and the cost-ef-
fectiveness of methadone in comparison with other opioids or con-
ventional PCA in the different surgeries. Nevertheless, the findings of
this study suggest that it is opportune to reappraise the use of metha-
done in the perioperative period.
Declaration of competing interest
None.
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